Health Care/Hospital
Korea Ginseng Corp. (JungKwanJang) Receives 'Tyler Award' from American Botanical Council
- The American Botanical Council (ABC) selects institutions that contribute to scientific research on natural products worldwide. CERRITOS, Calif., March 11, 2025 /PRNewswire/ -- Korea Ginseng Corp. (KGC), known for its flagship brand JungKwanJang, received the 'Tyler Award (Varro E. Tyler Award...
2025-03-11 18:40
1867
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
* Ranking in top 1% of S&P Global CSA Score * Inclusion in Global Yearbook for third consecutive year * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Develop...
2025-03-11 11:18
2873
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...
2025-03-11 08:00
1847
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...
2025-03-11 08:00
1943
Protecting Women's Health: Visionary's Precision Cervical Cancer Screening Public Welfare Activity Brings Health Blessings to Women
TORONTO, March 10, 2025 /PRNewswire/ -- On March 8, 2025, the public welfare activity of "Celebrating International Women's Day and Caring for Women's Health" and the "Global Press Conference of E7 Protein Detection Kit" were successfully held inHong Kong, China. This event was hosted by (Canada)...
2025-03-11 04:00
5875
Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in the North American Market
BEIJING, March 10, 2025 /PRNewswire/ -- Wingderm® once again participated in the 2025 AAD Annual Meeting, which was held inOrlando, Florida, from March 7 to 9. The American Academy of Dermatology is the largest, most influential, and most representative dermatologic association. During the event,...
2025-03-11 01:00
2334
TCI Biotech Announces Strong 2024 Financial Performance, Sets Sights on Global Growth in 2025
TAIPEI, March 10, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year endingDecember 31, 2024. The company reported steady revenue performance, stron...
2025-03-10 23:00
2730
World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection
Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings without raising recall rates, presenting a game-changing tool for countries relying on single-reader mammography screening SEOUL, South Korea, March 10, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a le...
2025-03-10 21:00
2498
RITFIT Calls for Real Strength to Accelerate Action on International Women's Day
CHINO HILLS, Calif., March 10, 2025 /PRNewswire/ -- This March, RITFIT has launched a series of events under the theme "Empowering Women: Health and Strength in the Home Gym," in alignment with this year's International Women's Day theme, "Accelerate Action." The initiative encourages women to pr...
2025-03-10 20:30
4962
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers,today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...
2025-03-10 10:53
1996
RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase I/...
2025-03-10 09:30
2382
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
* OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by theFDA * Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] * The ava...
2025-03-10 07:16
2445
Health In Tech to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
STUART, Fla., March 7, 2025 /PRNewswire/ -- Health In Tech (NASDAQ: HIT), an Insurtech platform company backed by third-party AI technology, today announced that it will release financial results for the fourth quarter and full year endedDecember 31, 2024, following the close of market on Monday,...
2025-03-08 05:30
5185
JungKwanJang to Showcase Functional Red Ginseng Solutions at 2025 Natural Products Expo West
- Global No.1 red ginseng brand JungKwanJang participates in NPEW for 4 consecutive years, introduces new functional red ginseng products - First release of 3 new 'Everytime' products specialized for sports activities… Scheduled to be available on Amazon in March ANAHEIM, Calif., March 7, 20...
2025-03-07 18:03
3076
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pemb...
2025-03-07 13:03
2056
THE BRACCO GROUP: OFFICIAL GOLD SPONSOR OF THE ITALY PAVILION AT THE OSAKA EXPO 2025
At the Japanese World Expo, to be held from April 13 to October 13, 2025, the Bracco Group will be a key contributor on the themes of art, technology and medicine of the future. In addition to several scientific events organized by Bracco Japan, a ballet by the La Scala Academy onItaly's National...
2025-03-07 07:30
2891
NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'
Pioneering a Paradigm Shift in Pain Treatment, Accelerating Global Market Expansion SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable microsphere for muscu...
2025-03-06 22:00
2620
Lunit Expands Partnership with Saudi Arabia's Largest Medical Group to Deploy AI Chest X-Ray Solution
Following last year's success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical Group, analyzing 1 million chest X-rays over three years SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics an...
2025-03-06 22:00
3435
GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy
SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has receivedclearance from the U.S Food and Drug Administration(FDA) for its Investigational...
2025-03-06 17:00
1720
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibod...
2025-03-06 08:30
2188
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 289 media titles]
2026-01-05 12:14
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 280 media titles]
2026-01-06 10:45
Hyundai Motor Group Executive Chair Chung Presents 2026 Vision: Customer-Focused Transformation and AI-Driven Ecosystem Collaboration
[Picked up by 264 media titles]
2026-01-05 09:10
Pepsi & 7UP Team Up with Disney on Zootopia 2, Sparking Fresh Wave of Crossover Youthful Energy
[Picked up by 256 media titles]
2025-12-31 12:53
Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8220
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
7313
